vt3989
vivace therapeutics
['mesothelioma', 'concept data', 'vt3989']
 2023 update: 1st clinical proof-of-concept data for #cancer drug targeting hippo pathway, previously considered undruggable. vivace therapeutics vt3989 well-tolerated with durable antitumor response in patients with advanced malignant #mesothelioma. 
We’re an early-stage VC firm that invests in entrepreneurs with visionary ideas who want to make a difference in technology and healthcare.